Skip to Main content Skip to Navigation
Master Thesis

Mid-term impact of infliximab metaoptimization on surgical rates in severe inflammatory bowel disease: 3-year follow up

Abstract : Background: severe IBD patients are prone to increased drug clearance via accelerated drug metabolism as well as excess loss through fecal excretion and may require higher doses of infliximab (IFX) to achieve appropriate pharmacokinetics and drug concentrations. Exactly how to optimize accelerated dosing strategies remains an unanswered question. Method: Our aim was to evaluate the efficacy of metaoptimized IFX (MIFX), i.e. combined intensified induction and maintenance regimen as compared to a standard IFX (SIFX) schedule historical cohort on 3-year surgical rates. In this retrospective single center study, two cohorts of patients with CD and UC who were hospitalized at our single teaching hospital for an acute severe flare were identified from 2014 to 2016 (MIFX cohort) and 2007 to 2014 (SIFX cohort) were identified. Severe UC and CD were defined per clinical assessment with a Lichtiger Index > 12 for UC, a Harvey Bradshaw Index (HBI) > 12 for CD and according to ECCO classification. Results: 15/46 (35.6%) MIFX had undergone surgery, against 21/49 (43.8%) in SIFX group, after 3 year of follow up. SIFX patients are 1.6-fold chance of not being surgery-free at 3 year than MIFX patients (OR 1.6 [95% IC: 0.633-4.255], p=0.308). Conclusion: Our study suggests that, in our real-life practice, severe selected IBD patients with IFX metaoptimization had more persistent and higher chance of being surgery-free at the mid-term without carrying an increased risk for infection.
Document type :
Master Thesis
Complete list of metadata

https://dumas.ccsd.cnrs.fr/dumas-03409433
Contributor : Jean-Hugues Morneau Connect in order to contact the contributor
Submitted on : Tuesday, November 2, 2021 - 4:18:57 PM
Last modification on : Thursday, November 4, 2021 - 3:42:46 AM

File

2020GRAL5147_bastide_laetitia_...
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-03409433, version 1

Citation

Laetitia Bastide. Mid-term impact of infliximab metaoptimization on surgical rates in severe inflammatory bowel disease: 3-year follow up. Human health and pathology. 2020. ⟨dumas-03409433⟩

Share

Metrics

Record views

19

Files downloads

3